Literature DB >> 16052537

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

Joseph F Cortese, Ashok L Gowda, Anil Wali, James F Eliason, Harvey I Pass, Richard B Everson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16052537     DOI： 10.1002/ijc.21271

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  8 in total

1.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Authors:  Giulia Pinton; Warren Thomas; Paolo Bellini; Arcangela Gabriella Manente; Roberto E Favoni; Brian J Harvey; Luciano Mutti; Laura Moro
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

3.  Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.

Authors:  K Okuda; H Sasaki; O Kawano; H Yukiue; T Yokoyama; M Yano; Y Fujii
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-08       Impact factor: 4.553

4.  Investigational approaches for mesothelioma.

Authors:  Veerle F Surmont; Eric R E van Thiel; Karim Vermaelen; Jan P van Meerbeeck
Journal:  Front Oncol       Date:  2011-08-22       Impact factor: 6.244

Review 5.  New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.

Authors:  Svetlana Kotova; Raymond M Wong; Robert B Cameron
Journal:  Cancer Manag Res       Date:  2015-01-23       Impact factor: 3.989

6.  Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Authors:  B J Stish; S Oh; H Chen; A Z Dudek; R A Kratzke; D A Vallera
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 9.075

Review 7.  Systemic treatments for mesothelioma: standard and novel.

Authors:  Hedy Lee Kindler
Journal:  Curr Treat Options Oncol       Date:  2008-09-03

8.  Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.

Authors:  R Mezzapelle; U Miglio; O Rena; A Paganotti; S Allegrini; J Antona; F Molinari; M Frattini; G Monga; O Alabiso; R Boldorini
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.